Protagenic Therapeutics enters ATM equity offering agreement for up to $10M

Protagenic Therapeutics, Inc.new

Entered into ATM Sales Agreement with B. Riley Securities and EF Hutton to sell up to $10M of common stock.
Commission of 3.0% of gross sales price; agents use commercially reasonable efforts to sell shares.
Offering made under S-3 shelf registration (No. 333-256790) effective June 23, 2021.
Company not obligated to sell shares; agreement can be terminated by either party upon notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.